Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1521/prev.2011.98.3.287 | DOI Listing |
Sci Rep
January 2025
Institute of Geomechanics, Chinese Academy of Geological Sciences, Beijing, 100081, China.
Loess is extensively developed on both sides of the Longwu River, a tributary of the Yellow River, Tongren County, Qinghai Province. The engineering geological characteristics are complex, and landslide disasters are highly developed. Based on field geological surveys and physical property analysis of the loess in this area, this study analyzes the influence of water content, consolidation pressure, and soil disturbance on the dynamic characteristics of loess using GDS dynamic triaxial tests.
View Article and Find Full Text PDFDiabetologia
January 2025
MRC Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
Aims/hypothesis: UK standard care for type 2 diabetes is structured diabetes education, with no effects on HbA, small, short-term effects on weight and low uptake. We evaluated whether remotely delivered tailored diabetes education combined with commercial behavioural weight management is cost-effective compared with current standard care in helping people with type 2 diabetes to lower their blood glucose, lose weight, achieve remission and improve cardiovascular risk factors.
Methods: We conducted a pragmatic, randomised, parallel two-group trial.
Trials
January 2025
Center for AIDS Prevention Sciences, Division of Prevention Science, University of California, San Francisco, USA.
Background: Disparities persist in testing and treatment for hepatitis C virus (HCV), leaving socially marginalized populations, including people who inject drugs (PWID), less likely to benefit from curative treatment. Linkage services are often insufficient to overcome barriers to navigating the medical system and contextual factors.
Methods: The You're Empowered for Treatment Initiation (YETI) Partner trial is a single-site randomized controlled trial evaluating the efficacy of a two-session behavioral intervention that engages injecting partners as peer navigators for HCV treatment.
Drugs Real World Outcomes
January 2025
Interventional Radiology Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Background: The combination of regorafenib and immune checkpoint inhibitor (ICI) has been the most popular second-line systemic therapy for advanced hepatocellular carcinoma (HCC). However, considering the good anti-tumor performance of lenvatinib, combined immunotherapy on the basis of lenvatinib after first-line lenvatinib failure is also popular in clinical practice. This study aimed to compare the efficacy and safety of regorafenib plus ICI (TACE-R-I) versus lenvatinib plus ICI (TACE-L-I) in patients with advanced HCC after lenvatinib failure.
View Article and Find Full Text PDFClin Orthop Relat Res
January 2025
Senior Editor, Clinical Orthopaedics and Related Research®, Schaumburg, IL, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!